Abstract :
Background: To compare the efficiency of dorzolamide + timolol fixed
combination vs. the Brimonidine + timolol fixed combination in the management
of primary open-angle glaucoma Materials and methods: A prospective study
conducted over a period of 6 months with a total of 69 patients having primary open
angle glaucoma (POAG) who completed a follow up of 6 months at a tertiary care
hospital. Detailed history of the patient was obtained and patients were assessed for
best corrected visual acuity, base line IOP with Goldmann applanation tonometer and
detailed anterior and posterior segment examination. They were categorized into two
groups according to the combinations prescribed by the ophthalmologist as follow:
group 1-dorzolamide+timolol and group 2-brimonidine+timolol. A follow up
evaluation of each patient was done at 1, 3 and 6 months after baseline visit. Results:
During our study the baseline IOP for dorzolamide + timolol group was 25.7 ±4.25 mm
Hg and for brimonidine + timolol group was 26.3 ±5.86 mm Hg. During 6 months
treatment, the mean reduction in IOP was 7.83 mm Hg (29.4%) in dorzolamide +
timolol group and 9.39 mm Hg (35.6%) in brimonidine + timolol group. Conclusion: Our
study showed that brimonidine + timolol combination has superiority over
dorzolamide + timolol to reduce the IOP in newly diagnosed patients with POAG The
value of IOP reduction in our study in brimonidine + timolol group was 9.39 mm Hg
(35.6%) and 7.83 mm Hg (29.4%) in dorzolamide + timolol group.
Keyword :
Primary open angle glaucoma, brimonidine, timolol, dorzolamide